ABAXIS, Inc. (NASDAQ:ABAX) is expected to pay $0.14 on Dec 15, 2016. The indicated annual dividend is $0.56. Shareholders owning the stock before Nov 29, 2016 will be eligible to receive the payout. Based on ABAXIS, Inc.’s current price of $53.37, the dividend is 0.26%. This dividend’s record date is Dec 1, 2016 and the announcement date is Nov 10, 2016. The stock increased 1.19% or $0.63 on November 25, hitting $53.37. Abaxis Inc (NASDAQ:ABAX) has risen 17.25% since April 25, 2016 and is uptrending. It has outperformed by 11.23% the S&P500.
Abaxis, Inc. is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The company has a market cap of $1.22 billion. The Firm markets and sells its products around the world through independent distributors and direct sales force. It has a 35.13 P/E ratio. The Company’s divisions are the medical market and the veterinary market.
Insitutional Activity: The institutional sentiment increased to 1.24 in Q2 2016. Its up 0.17, from 1.07 in 2016Q1. The ratio is positive, as 19 funds sold all Abaxis Inc shares owned while 40 reduced positions. 11 funds bought stakes while 52 increased positions. They now own 22.80 million shares or 1.87% more from 22.38 million shares in 2016Q1.
Arizona State Retirement System last reported 0.01% of its portfolio in the stock. Moreover, Wells Fargo & Mn has 0.01% invested in Abaxis Inc (NASDAQ:ABAX) for 458,288 shares. Mycio Wealth Ltd Liability Com last reported 500 shares in the company. Moreover, Peak6 Lp has 0% invested in Abaxis Inc (NASDAQ:ABAX) for 3,980 shares. State Teachers Retirement holds 48,074 shares or 0.01% of its portfolio. Citigroup has 6,707 shares for 0% of their US portfolio. Ladenburg Thalmann Serv Incorporated holds 0% of its portfolio in Abaxis Inc (NASDAQ:ABAX) for 3,052 shares. Ubs Asset Mgmt Americas Inc owns 9,499 shares or 0% of their US portfolio. Employees Retirement Association Of Colorado holds 0% or 6,834 shares in its portfolio. Great West Life Assurance Can has 3,741 shares for 0% of their US portfolio. Us Comml Bank De, a Minnesota-based fund reported 34,182 shares. Advsr Asset Mngmt Incorporated owns 8,288 shares or 0.01% of their US portfolio. Millennium Management Ltd Limited Liability Company accumulated 0.01% or 95,105 shares. Susquehanna Group Inc Ltd Liability Partnership reported 42,115 shares or 0% of all its holdings. Prtnrs Ltd Liability Corporation last reported 0.09% of its portfolio in the stock.
Insider Transactions: Since June 8, 2016, the stock had 0 insider buys, and 6 sales for $1.03 million net activity. $150,000 worth of shares were sold by EVENHUIS HENK on Friday, August 5. $96,582 worth of Abaxis Inc (NASDAQ:ABAX) shares were sold by SEVERSON CLINTON. $426,778 worth of shares were sold by WOOD DONALD PETER on Tuesday, August 23. $49,500 worth of shares were sold by SINGH PRITHIPAL on Thursday, September 8. 5,000 shares were sold by BASTIANI RICHARD, worth $233,736 on Wednesday, June 8.
Abaxis Inc (NASDAQ:ABAX) Ratings Coverage
Out of 6 analysts covering Abaxis (NASDAQ:ABAX), 0 rate it a “Buy”, 3 “Sell”, while 3 “Hold”. This means 0 are positive. $62 is the highest target while $39 is the lowest. The $42 average target is -21.30% below today’s ($53.37) stock price. Abaxis has been the topic of 11 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Credit Suisse initiated Abaxis Inc (NASDAQ:ABAX) rating on Thursday, February 4. Credit Suisse has “Underperform” rating and $39 price target. The rating was downgraded by Bank of America to “Underperform” on Wednesday, October 21. As per Friday, July 22, the company rating was downgraded by Feltl & Co. The rating was initiated by CL King on Friday, April 1 with “Neutral”. The stock of Abaxis Inc (NASDAQ:ABAX) has “Hold” rating given on Thursday, November 12 by Canaccord Genuity. The firm has “Hold” rating by Canaccord Genuity given on Friday, April 1. The firm has “Buy” rating given on Thursday, July 23 by Canaccord Genuity. Canaccord Genuity maintained the stock with “Hold” rating in Thursday, October 29 report.
More recent Abaxis Inc (NASDAQ:ABAX) news were published by: Prnewswire.com which released: “Abaxis Reports Financial Performance for the Second Quarter of Fiscal 2017” on October 25, 2016. Also Medgadget.com published the news titled: “Veterinary Biochemistry Analyzers Market: Increasing incidences of disease …” on June 07, 2016. Prnewswire.com‘s news article titled: “Abaxis, Inc. And Banfield Pet Hospital® Enter Into Exclusive Five-Year Supply …” with publication date: November 11, 2015 was also an interesting one.
ABAX Company Profile
Abaxis, Inc., incorporated on January 12, 1989, is a developer, maker and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Firm markets and sells its products around the world through independent distributors and direct sales force. The Company’s divisions are the medical market and the veterinary market. The Company’s subsidiary, Abaxis Europe GmbH, markets and distributes diagnostic systems for medical and veterinary uses in the European and Asia Pacific markets.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.